ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 807

B Cells in Giant Cell Arteritis: a Novel Target for Treatment?

Jacoba C. Graver1, Maria Sandovici2, Wayel H. Abdulahad2, Erlin A. Haacke3, Annemieke M.H. Boots2 and Elisabeth Brouwer4, 1Rheumatoloy and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 4Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: B cells and giant cell arteritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is the most common type of systemic vasculitis. Currently, two forms of GCA are described: a cranial(C)-GCA (temporal arteritis) and a systemic, large-vessel (LV)-GCA. Late complications of LV-GCA are aortic aneurysms or aortic rupture. Based on the analysis of temporal artery tissue, GCA is postulated to start at the adventitial site and to be T cell-mediated. In the temporal artery infiltrates, T cells clearly outnumber B cells. However, our report on a disturbed homeostasis of B cells in newly diagnosed C-GCA patients shows evidence for a putative role of B cells in GCA.1 Recently, the presence of B cells organized in artery tertiary lymphoid organs (ATLOs) has been described in C-GCA.2 The immunopathological role of B cells in both forms of GCA is underexplored and it is unknown whether B cells are present in the vessel wall of patients with LV-GCA. The objective of this study was to assess the presence and organization of B cells in the aorta of patients with LV-GCA.
Methods: Aorta tissue samples of 11 histologically-proven LV-GCA patients who underwent surgery due to an aortic aneurysm were studied by immunohistochemistry. Staining was performed with antibodies against CD20 (B cells), CD3 (T cells), CD21 (follicular dendritic cells (FDC)), PNAd (high endothelial venules (HEV)), bcl6 (germinal centers), and CD138 (plasma cells). None of the patients was receiving immunosuppressive treatment at the time of surgery. For comparison 22 aorta samples from age- and sex-matched atherosclerosis patients with an aortic aneurysm were included.
Results: Aorta tissues of LV-GCA patients showed massive infiltration of B cells (see fig. 1). The infiltrating B cells were mainly found in the adventitia and were organized into high density B cell areas. In contrast to the temporal artery, B cells outnumbered T cells in the aorta. Besides the presence of T cells, FDC, germinal centers, plasma cells, and HEV were documented at the areas of B cell infiltrates, which are typical for organized ATLOs.
Conclusion: Aorta tissues from patients with histologically-proven LV-GCA showed massive and organized B cell infiltrates mostly located in the adventitia. The mere presence of B cells at the site of inflammation prompts further investigation into the role of B cells in the pathogenesis of GCA.

1.             van der Geest KSM, Abdulahad WH, Chalan P, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Art  Rheumatol. 2014;66(7):1927-1938.

2.             Ciccia F, Rizzo A, Maugeri R, et al. Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis. Ann Rheum Dis. 2016;0:1-9.

Fig. 1. Aorta from a LV-GCA patient with organized high density
CD20+ B cells areas in the adventitia (DAB/brown).

 


Disclosure: J. C. Graver, None; M. Sandovici, None; W. H. Abdulahad, None; E. A. Haacke, None; A. M. H. Boots, None; E. Brouwer, None.

To cite this abstract in AMA style:

Graver JC, Sandovici M, Abdulahad WH, Haacke EA, Boots AMH, Brouwer E. B Cells in Giant Cell Arteritis: a Novel Target for Treatment? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/b-cells-in-giant-cell-arteritis-a-novel-target-for-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/b-cells-in-giant-cell-arteritis-a-novel-target-for-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology